301. Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level.
- Author
-
Kim YG, Suh JW, Kang SH, Park JJ, Yoon CH, Cho YS, Youn TJ, Chae IH, Choi DJ, and Kim HS
- Subjects
- Aged, Biomarkers blood, Blood Platelets metabolism, Clopidogrel, Coronary Disease blood, Coronary Disease diagnosis, Drug-Eluting Stents, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors adverse effects, Predictive Value of Tests, Randomized Controlled Trials as Topic, Receptors, Purinergic P2Y12 blood, Reproducibility of Results, Retrospective Studies, Risk Factors, Smoking adverse effects, Ticlopidine adverse effects, Ticlopidine therapeutic use, Treatment Outcome, Blood Platelets drug effects, Coronary Disease therapy, Hemoglobins metabolism, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Platelet Aggregation Inhibitors therapeutic use, Platelet Function Tests, Receptors, Purinergic P2Y12 drug effects, Smoking blood, Ticlopidine analogs & derivatives
- Abstract
Objectives: The authors performed this analysis to examine whether the enhanced clopidogrel responsiveness in current smokers is maintained after adjusting the influence of hemoglobin on VerifyNow P2Y12 reaction unit (PRU)., Background: PRU is consistently reported to be lower in current smokers. However, PRU has a significant inverse relationship with hemoglobin level, and smokers have higher hemoglobin levels. Because the association between PRU and hemoglobin is likely to be an in vitro phenomenon, we hypothesized that the observed difference in PRU between nonsmokers and current smokers is the result of confounding effect of hemoglobin rather than true difference in platelet reactivity., Methods: Three cohorts were combined for the analysis (SNUBH [Seoul National University Bundang Hospital], n = 459; CILON-T [influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation], n = 715; HOST-ASSURE [Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen], n = 1,357). The final combined cohort consisted of 1,314 patients who underwent percutaneous coronary intervention and had VerifyNow P2Y12 assay results. General linear model (analysis of covariance) was used to control the effect of hemoglobin on PRU., Results: A significant inverse correlation was observed between PRU and hemoglobin (r = -0.389; p < 0.001). Current smokers showed a significantly higher hemoglobin level (13.5 ± 1.6 vs. 14.4 ± 1.5; p < 0.001) but lower PRU level (230.1 ± 90.7 vs. 212.2 ± 83.6; p < 0.001). After adjusting the influence of hemoglobin on PRU, there was no difference in PRU between nonsmokers and current smokers (224.1 [95% confidence interval: 218.7 to 229.5] vs. 225.3 [95% confidence interval: 217.2 to 233.3]; p = 0.813)., Conclusions: The observed difference in PRU between nonsmokers and current smokers is largely attributable to the difference in hemoglobin level. Enhanced clopidogrel responsiveness in cigarette smokers is not confirmed in this study and the concept of the smokers' paradox needs further validation., (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF